Regarding other members of the HER family, in non-small cell lung cancer (NSCLC), synergy has been shown between HDIs and the HER1 (EGFR) tyrosine kinase inhibitors erlotinib and gefitinib (Witta et al, 2006). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.